Merck bets on generic biologics
Merck is planning to sell generic copies of blockbuster biotech drugs, the drug maker announced today (Dec. 9) at the annual business briefing at its New Jersey headquarters. Through the newly announced Merck BioVentures division, the company is setting its sights on biotech copycats, which still require their own clinical trials and cost millions to develop. As a result, these drugs are generally priced only marginally lower than branded versions and can still be a lucrative venture. The noti
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
**Related stories:__***linkurl:Merck to cut jobs;http://www.the-scientist.com/blog/display/55103/
[22nd October 2008]*linkurl:Generic drugs;http://www.the-scientist.com/article/display/15551/
[20th June 2005]*linkurl:FDA caution tempers race for generic biologics;http://www.the-scientist.com/article/display/14194/
[20th October 2003]
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Meet the Author
Elie Dolgin
This person does not yet have a bio.View full profile
Share
